



Contacts:

Judy Cerne, President & CEO
McKinney Advertising & Public Relations
Phone: 216/621-5133 Fax: 216/621-1181
E-mail: jcerne@mckinneyad.com

Pamela P. Boggs, MBA, Director of Education & Development
The North American Menopause Society
Phone: 440/442-7658 Fax: 440/442-2660

**CONFUSION ABOUT MENOPAUSAL
HORMONE THERAPY NOW CLARIFIED BY
THE NORTH AMERICAN MENOPAUSE SOCIETY**

Location

5900 Landerbrook Drive
Suite 390
Mayfield Heights, OH 44124

Mailing Address

Post Office Box 94527
Cleveland, OH 44101-4527

Telephone: 440/442-7550

Fax: 440/442-2660

E-Mail: info@menopause.org

Web Site: www.menopause.org

2007/2008 President

Victor W. Henderson, MD, MS

2007/2008 Board of Trustees

Thomas B. Clarkson, DVM
Elizabeth Contestabile, RNC, BScN

Robert R. Freedman, PhD

Steven R. Goldstein, MD

Victor W. Henderson, MD, MS

Risa Kagan, MD

JoAnn V. Pinkerton, MD

Nancy K. Reame, MSN, PhD

Marilyn L. Rothert, PhD, RN

Leon Speroff, MD

Cynthia A. Stuenkel, MD

Michelle P. Warren, MD

Ex Officio

Isaac Schiff, MD

Wulf H. Utian, MD, PhD

Central Office Staff

Wulf H. Utian, MD, PhD

Executive Director

Pamela P. Boggs, MBA

*Director of Education
and Development*

Carolyn Develen

Administrative Director

General Counsel

Kenneth W. Kleinman, Esq.

CLEVELAND, Ohio (June 24, 2008)—Updated clinical recommendations for hormone therapy (HT) for postmenopausal women based on the best available evidence have just been released by The North American Menopause Society (NAMS). Entitled “Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society,” the document was developed by an Advisory Panel of fourteen clinicians and researchers expert in this area of women’s health, then approved by the NAMS Board of Trustees.

Endorsed by such distinguished organizations as the Society for Obstetricians and Gynaecologists of Canada, this modified position statement incorporates the most recent evidence regarding HT use for menopause-related symptoms (including hot flashes and vaginal dryness) and also discusses the risks and benefits of HT on sexual function, urinary health, osteoporosis, cardiovascular effects, diabetes, breast and endometrial cancer, mood, and cognition.

(more)

“The newest NAMS position statement on hormone therapy considers the current best practice of medicine from a clinical perspective. The undue fear and confusion generated in recent years by overrepresentation or misinterpretation of clinical studies mandated a clearer explanation of the therapeutic benefit-risk ratio of HT after menopause, and how these benefits and risks affect both health providers and the women weighing the use of such therapy,” said Wulf H. Utian, MD, PhD, NAMS Executive Director and Chair of the Advisory Panel that developed the new document. “The Society has included a broad spectrum of topics related to HT use for postmenopausal women and provided an addendum to understand and explain risk, clarified by the world’s most respected experts in the field.”

This statement has also been endorsed by the American Medical Women’s Association, The Endocrine Society, the National Association of Nurse Practitioners in Women’s Health, and the National Women’s Health Resource Center.

The position statement will be published in the July/August 2008 issue of the Society’s official journal, *Menopause*, but is now posted ahead of print on the publisher’s Web site, accessible by subscribers. An unembargoed PDF of the paper is available at www.menopause.org/PSHT08.pdf. Also note that a set of slides that summarize the paper’s contents is available without charge on the NAMS Web site (<http://www.menopause.org/aboutmeno/consensus.aspx>).

The Mission of NAMS, a nonprofit scientific organization, is to promote the health and quality of life of women through an understanding of menopause. The Society’s membership of 2,000 professionals representing a variety of disciplines—including clinical and basic science experts from medicine, nursing, pharmacy, anthropology, sociology, psychology, and complementary/alternative medicine—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause. (www.menopause.org)

###